6550--Notice Of Intent to Sole Source - EUROIMMUN T-SPOT Test Southeast Louisiana Veterans Health Care System (SLVHCS) POP: 10/1/2025 through 09/30/2026

Key Dates
Due Date

-

Posted Date

-

Agency & Value
Agency

256-NETWORK CONTRACT OFFICE 16 (36C256)

Contract Value

Not provided

Codes & Classification
Solicitation Number

36C25625Q1502

NAICS

325413 - In-Vitro Diagnostic Substance Manufacturing

Classification Code

6550

Additional Details
Set Aside

None

Place of Performance

-

SourceSAM
Documents2
The Department of Veterans Affairs, through its Network Contracting Office (NCO) 16, has issued a Special Notice indicating its intent to award a sole-source, firm-fixed-price contract for the provision of EUROIMMUN T-SPOT Tuberculosis (TB) testing services and associated equipment to the Southeast Louisiana Veterans Health Care System (SLVHCS). The anticipated period of performance for this contract is from October 1, 2025, through September 30, 2026. This procurement is classified under NAICS code 325413, which pertains to In-Vitro Diagnostic Substance Manufacturing, and utilizes Product Service Code 6550. The contract will be awarded to Euroimmun Inc., located at 1 Bloomfield Ave, Mountain Lakes, New Jersey, as the only responsible source capable of meeting the agency’s requirements under the authority of 41 U.S.C 253(c)(1) and FAR 6.302-1. The scope of this contract encompasses the supply and maintenance of the Auto-Pure 20B instrument, as well as all necessary reagents, standards, controls, consumables, disposable items, parts, accessories, and an Uninterruptible Power Supply (UPS). Euroimmun will also provide service coverage and any other items required for the proper operation of the contractor-owned instrument, specifically for T-SPOT TB testing utilizing Peripheral Blood Mononuclear Cells (PBMC) isolation. These services are essential for the generation of Microbiology Cost Per Reportable Result (CPRR) services within the Pathology and Laboratory Medicine Service (P&LMS), Microbiology/Molecular Pathology Section, located at Room 4F122, 2400 Canal St, New Orleans, LA 70119. The contract will include Clause 52.217-9, Option to Extend the Term of the Contract, allowing for potential extension at the government’s discretion. The procurement is not a request for quotations; however, interested parties may submit a capabilities statement by September 26, 2025, at 13:00 AM CST to the primary contact, Christopher Rossi ([email protected]), referencing procurement identifier 36C25625Q1502. Capabilities statements must provide clear and unambiguous evidence of the ability to meet the specified requirements. Registration in the System for Award Management (SAM) is mandatory for eligibility. It is important to note that the government reserves the right to proceed with a sole-source award regardless of responses received, should it be determined to be in the best interest of the government. All responses will be considered solely for the purpose of determining whether to conduct a competitive procurement. This opportunity is managed by the 256-Network Contract Office 16, a federal office responsible for contracting activities within the region. Contractors evaluating this opportunity should ensure their capabilities align with the specialized requirements for in-vitro diagnostic substance manufacturing and the provision of integrated equipment and service solutions for TB testing in a clinical laboratory setting. The contract’s scope and deliverables are expected to remain consistent throughout the lifecycle, focusing on reliable supply, maintenance, and operational support for the designated testing platform. For further details and to access the official notice, interested parties may visit the SAM.gov opportunity page at https://sam.gov/opp/0dd07cd2a7034d5f8423ecd179b62ce1/view.